Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
Siemens Healthineers agreed to acquire Novartis AG's (NYSE:NVS) diagnostics arm for $223.5 million (200 million euros) in a deal meant to enhance its cancer treatments.
西门子Healthineers同意以2.235亿美元（2万欧元）的价格收购诺华股份公司（纽约证券交易所代码：NVS）的诊断部门，该交易旨在加强其癌症治疗。
Both companies confirmed the acquisition, and it involved Advanced Accelerator Applications, a division Novartis purchased in 2017.
两家公司都确认了此次收购，其中涉及诺华在2017年收购的高级加速器应用程序部门。
The Financial Times reported that Advanced Accelerator Applications operates Europe's second-largest network of cyclotrons. The unit produces radioactive compounds essential for positron emission tomography (PET) scans that detect cancer and other diseases.
《金融时报》报道说，高级加速器应用程序运营着欧洲第二大回旋加速器网络。该装置生产的放射性化合物对检测癌症和其他疾病的正电子发射断层扫描（PET）扫描至关重要。
Also Read: Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug.
另请阅读：法官裁定诺华停止其最畅销的心脏病药物的仿制药上市。
The deal will expand Siemens Healthineers' PET radiopharmaceuticals business—the world's largest—into Europe, strengthening its leading position in the imaging market, the Financial Times report adds.
《金融时报》报道补充说，该协议将把西门子Healthineers的pET放射性药物业务——全球最大的业务——扩展到欧洲，巩固其在影像市场的领先地位。
PET scans, often used for diagnosing cancers like lung, breast, and cervical cancer, have become increasingly vital, especially in monitoring cancer spread and treatment response. While PET imaging is more costly and limited in European state-run healthcare systems compared to other techniques like MRI, it is now considered a standard diagnostic tool for certain cancer types.
pET 扫描通常用于诊断肺癌、乳腺癌和宫颈癌等癌症，已变得越来越重要，尤其是在监测癌症扩散和治疗反应方面。尽管与磁共振成像等其他技术相比，在欧洲国营医疗系统中，pET 成像成本更高且受限，但它现在被认为是某些癌症类型的标准诊断工具。
Erlangen, Germany-based Siemens Healthineers, spun off from Siemens in 2017, sees the acquisition as strategically critical. The radioactive compounds used in PET scans have a short half-life and must be administered on the day they are produced, necessitating localized production close to patients.
总部位于德国埃尔兰根的西门子Healthineers于2017年从西门子分拆出来，认为此次收购具有战略意义。pET扫描中使用的放射性化合物的半衰期很短，必须在生产当天给药，因此需要在患者附近进行局部生产。
Siemens Healthineers' imaging division remains the company's largest revenue generator, contributing nearly 3 billion euros in sales in the last quarter, accounting for over half of total group revenues.
西门子Healthineers的成像部门仍然是该公司最大的收入来源，在上个季度贡献了近30欧元的销售额，占集团总收入的一半以上。
Novartis decided to sell Advanced Accelerator Applications' diagnostics unit, viewing it as a low-growth segment.
诺华决定出售高级加速器应用程序的诊断单元，将其视为低增长细分市场。
The pharma giant acquired Advanced Accelerator Applications for $3.9 billion to gain access to its innovative radiopharma drugs, including Lutathera, a treatment for neuroendocrine tumors expected to generate $704 million in sales this year.
这家制药巨头以39亿美元的价格收购了Advanced Accelerator Applications，以获得其创新的放射性药物药物，包括Lutathera，一种治疗神经内分泌肿瘤的药物，预计今年将创造7.04亿美元的销售额。
Novartis noted that a dedicated diagnostics owner would better support molecular imaging's growth prospects, leading to this divestiture.
诺华指出，专门的诊断所有者将更好地支持分子成像的增长前景，从而导致这种剥离。
In addition to the sale, Novartis and Siemens Healthineers will collaborate to enhance the supply of nuclear isotopes used in radiopharma drugs like Lutathera.
除出售外，诺华和西门子Healthineers还将合作增加用于Lutathera等放射性药物的核同位素的供应。
Price Action: NVS stock is up 0.47% at $119.12 during the premarket session at last check Monday.
价格走势：周一最后一次盘前交易中，NVS股价上涨0.47％，至119.12美元。
- Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer.
- 来自默沙东、百时美和百济神州的抗癌药物受到质疑，因为美国食品药品管理局委员会将讨论限制用于胃癌的PD-1药物。